OncRef

Clinical Trial: NCT03824483

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:Memorial Sloan Kettering Cancer Center
Information Provided By:Memorial Sloan Kettering Cancer Center
Last Update Posted:2026-09-03

Study Overview

Brief Summary

The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.

Official Title

Phase 2 Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) and Mantle Cell Lymphoma (MCL)

Conditions

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)

Intervention / Treatment

  • Drug: Zanubrutinib
  • Drug: Obinutuzumab
  • Drug: Venetoclax

Other Study ID Numbers

  • 18-427

Start Date (Actual)

2019-02-22

Primary Completion Date (Estimated)

2027-02

Study Completion Date (Estimated)

2027-02

Enrollment (Estimated)

230

Study Type

Interventional

Phase

Phase 2